In July 2016 BMC supported OncoArendi Therapeutics in grant application for the project “Development of a first-in-class small molecule drug candidate for cancer treatment through YKL 40 inhibition” in the 1/1.1.1/2016 (“Fast track”) program by The National Centre for Research and Development.
The project included substantive preparation of the grant application parts, concerning:
– market (target market characteristics, demand for project results analysis , competitive environment)
– project’s profitability (preliminary valuation of the project).
The application received the maximum possible point value and was recommended for funding in the amount of 5,5 M EUR.